EU/3/12/1021: Orphan designation for the prevention of poliomyelitis in patients with immunodeficiencies deemed at risk

1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene

Overview

On 17 July 2012, orphan designation (EU/3/12/1021) was granted by the European Commission to ProPhase Development Ltd, United Kingdom, for 1-[(2-chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene for the prevention of poliomyelitis in patients with immunodeficiencies deemed at risk.

The sponsorship was transferred to ViroDefense Ltd, United Kingdom, in January 2013.

Key facts

Active substance
1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene
Intented use
Prevention of poliomyelitis in patients with immunodeficiencies deemed at risk
Orphan designation status
Positive
EU designation number
EU/3/12/1021
Date of designation
17/07/2012
Sponsor
ViroDefense Ltd
The Catalyst
Suite G17
University of York
Baird Lane
York
YO10 5GA
United Kingdom
Tel. +44 (0)1904 567660

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating